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I N T R O D U C T I O N A N D O B J E C T I V E S 
T r a d i t i o n a l l y the treatment of essential hypertension has been in accordance w i t h the 
stepped care approach as outlined o r i g i n a l l y b y the Hypertension Detection and F o l l o w - u p 
P r o g r a m ( H D F P ) 1 - 3 and supported b y the recommendations of the J o i n t National 
Committee on Detection, Evaluation and Treatment of High Blood P r e s s u r e . 4 W h i l e 
diuretics and beta-blockers have been utilized as step one agents, recent questions have 
been raised regarding the safety of these agents in m i l d h y p e r t e n s i o n . 5 , 6 , 7 
E xt r apo lat ion of the results f r o m the M u l i t p l e R i s k Factor Intervention T r i a l ( M R F I T ) 
has raised c r i t i c i s m of the use of diuretics as step one antihypertensive agents. 8 In the 
M R F I T , a greater number of deaths occurred in a subgroup of men in the Special 
Intervention ( S I ) group w i t h hypertension and abnormalities on resting 
electrocardiograms ( E K G s ) than in the Usual Care ( U C ) group. The SI group patients 
received higher doses of diuretics than the U C group patients and most of the deaths 
reported w e r e sudden and unexpected. O i f f o r d has proposed the increased incidence of 
deaths in the SI group in the M R F I T may have been due to diuretic induced hypokalemia 
predisposing those patients to sudden death. 9 Elevations In plasma cholesterol and glucose 
may also occur w i t h diuretic t h e r a p y . 1 0 One finding f r o m a 1 6 y e a r f o l l o w - u p study of 
5 2 0 9 adults indicates that an elevated serum cholesterol may be a predisposing factor f o r 
atherosclerotic e v e n t s . 1 1 A more recent study in lipid research has demonstrated a 
correlation between elevated serum lipids and 8n increased r i s k of c o r o n a r y heart 
d i s e a s e . 1 2 It is unknown what the effects of small changes in serum glucose alone have on 
coronary heart disease but the Framingham d a t a 1 1 suggest glucose intolerance is 8 r i s k 
factor f o r atherosclerotic disease. 
B e t a - b l o c k e r s , commonly used as alternative step one antihypertensive agents, have 
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potential disadvantages as w e l l . S i m i l a r to the d i u r e t i c s , the beta blockers m a / increase 
the r i s k of atherosclerotic heart disease due to t h e i r effects on l i p i d m e t a b o l i s m . 1 3 
B e t a - b l o c k e r s increase plasma triglycerides and decrease plasma high density lipoprotein 
( H D L ) cholesterol. H D L - c h o l e s t e r o l is thought to be cardioprotective and reductions in 
this fraction of serum lipids may increase the r i s k of c o r o n a r y heart disease. A n 
additional disadvantage of beta-blocker t h e r a p y is that they are contraindicated in about 
2551 of hypertensive i n d i v i d u a l s . 5 Due to t h e i r physiologic changes such as a decrease in 
cardiac output and increase in p e r i p t e r a l resistance, b e t a - b l o c k e r s can cause c l i n i c a l l y 
significant adverse effects in patients w i t h p e r i p h e r a l vascular disease o r marginal 
cardiac function. T h e i r use should be avoided in these patients. B e t a - b l o c k e r s have 
different effects on glucose metabolism in nondiabetics, insulin-dependent and 
noninsulin-dependent d i a b e t i c s . 1 4 In insulin-dependent diabetic patients, beta-blockers 
can prolong, enhance o r mask the symptoms of hypoglycemia, w h i l e hyperglycemia tends 
to be the major effect in noninsulin-dependent diabetics. These effects on glucose 
metabolism may be significant in some diabetic patients and may prevent the concurrent 
administration of a b e t a - b l o c k e r In those individuals. F i n a l l y , in patients w i t h asthma, 
noncardioselective and even therapeutic doses of cardioselective b e t a - b l o c k e r s can 
antagonize b e t a - 2 adrenergic receptors in bronchial smooth muscle and induce 
bronchospasm. Noncardioselective beta-blockers should not be used and cardioselective 
beta-blockers should be used w i t h caution in patients w i t h asthma o r other bronchospastic 
lung disease. 
Due to the potential deleterious effects associated w i t h the use of diuretics and beta-
blockers as step one antihypertensives, f u r t h e r investigation of alternative drugs f o r the 
treatment of m i l d to moderate essential hypertension is warranted. A n ideal 
antihypertensive agent should be low in cost, have r e l a t i v e l y few side effects, be given in a 
simplified dosage regimen (once o r twice d a i l y ) and be f r e e of adverse effects on s er um 
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l ipids, glucose o r electrolytes. 
A surge of interest i n the use of calcium channel blockers in the treatment of 
hypertension is evident b y the number of recent r e p o r t s and symposia in the l i t e r a t u r e on 
this t o p i c . 1 5 - 2 2 Increases in Intracellular f r e e calcium concentrations facilitate smooth 
muscle cell contraction and increase vascular resistance w h i c h is a key underlying factor 
in essential hypertension. T w o mechanisms contribute to i n t r a c e l l u l a r calcium 
concentrations. F i r s t , the release of calcium f r o m i n t r a c e l l u l a r sites and second, 
increased p e r m e a b i l i t y of the cells to calcium b y the opening of calcium channels. 
Calcium channel blockers e x e r t t h e i r antihypertensive effects b y antagonizing the i n f l u x 
of calcium into vascular smooth muscle c e l l s . 2 3 " 2 5 T h e net r e s u l t is a decrease in 
intracellular calcium and vascular smooth muscle relaxation resulting in a decreese in 
blood pressure. 
Reviews of several studies w i t h the calcium channel blockers nifedipine and v e r a p a m i l 
have demonstrated t h e i r efficacy in the treatment of essential h y p e r t e n s i o n . 1 5 - 1 9 O n l y a 
few t r i a l s have been conducted on the efficacy of d i l t i a z e m . 2 6 - 3 2 Results have been 
favorable in showing the effectiveness of diltiazem i n essential hypertension in 
comparative studies w i t h p r o p r a n o l o l , 2 6 metoprolol 2 7 h y d r o c h l o r o t h i a z i d e , 2 8 ' 3 0 ' 3 1 
n i f e d i p i n e 2 9 and p l a c e b o 5 2 in these t r i a l s diltiazem was administered in either one fixed 
dose or the dose was titrated to a p a r t i c u l a r blood pressure response. Data f r o m the use of 
diltiazem in hypertensive patients Indicate that it has a r e l a t i v e l y benign side effect 
p r o f i l e . 2 0 - 3 1 The most common adverse effects of diltiazem w e r e dizziness, hypotension, 
flushing and bradycardia. 
The purpose of this investigation was to evaluate the clinical efficacy and side effect 
p r o f i l e of three dosages of diltiazem in a twice daily dosing regimen in the treetment of 
m i l d to moderate essential hypertension and to determine If a correlation between serum 
concentration and blood p r e s s u r e effect exists. 
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M E T H O D S 
Stud/ design. T h i s stud/ was part of a multicenter randomized, d o u b l e - b l i n d , 
placebo-controlled, p a r a l l e l , prospective stixfy. 
Patient selection. Patients w e r e recruited through the General Internal Medicine 
Clinic at the U n i v e r s i t y Hospital , U n i v e r s i t y of Utah. Patients taking antihypertensive 
medications w e r e w i t h d r a w n f r o m t h e i r medications f o r at least two weeks before baseline 
blood pressure measurements w e r e obtained. H y p e r t e n s i v e individuals w h o w e r e not 
being treated w i t h d r u g t h e r a p y w e r e evaluated f o r study qualification. Patients qualified 
i f the average of three resting supine diastolic blood pressures was i 9 5 m m H g and 
l O m m H g v a r y i n g b y no m x e than 7 m m H g on t w o consecutive outpatient v i s i t s which 
were separated b y f o u r to ten days. The average blood p r e s s u r e f r o m these two v i s i t s was 
used as the baseline value. A n y patient r e q u i r i n g longer than f o u r weeks to stabilize 
h i s / h e r blood pressure was considered labile and was excluded f r o m the study. 
Additionally , patients w e r e excluded i f any of the following conditions existed: weight 
greater than 3 0 * of their ideal body weight as determined b y the table in Appendix I , 
h i s t o r y of transient ischemic attacks o r s t r o k e s , carotid a r t e r y disease, acute myocardial 
infarction o r cardiovascular s u r g e r y w i t h i n the past y e a r , symptomatic coronary a r t e r y 
disease, congestive heart f a i l u r e , greeter than f i r s t degree heart block o r other 
conduction defects, renal disease ( S C r > 1.5mgSB) o r any other significant medical Illness. 
The study protocol was approved b y the Institutional Review Board at the U n i v e r s t i y of 
Utah. A l l patients signed a w r i t t e n informed consent document (Appen di x I I ) p r i o r to 
enrollment into the stud/. 
S t u d / protocol. D u r i n g the baseline evaluation period, a medical h i s t o r y and physical 
examination w e r e p e r f o r m e d and laboratory studies including an electrocardiogram 
( E K G ) , a chest X - r a y , complete blood count w i t h d i f f e r e n t i a l , u r i n a l y s i s and C h e m - 2 0 
were obtained. Patients w h o met the selection c r i t e r i a f o r t h i s stud/ w e r e randomized 
into one of f o u r treatment groups: placebo, 6 0 m g , 1 2 0 m g o r 1 8 0 m g ; each given b y the 
oral route twice daily- On day one a single dose of treatment agent was administered to the 
patient Blood pressure measures in the resting supine, Immediately standing and 
standing f o r f i v e minutes positions w e r e obtained p r i o r to d r u g administration and at 1 , 2 , 
3 , 4 , 6 , 8 , 1 0 , 1 2 , 1 6 , and 2 4 hours after the dose. Blood samples f o r serum 
concentration analyses w e r e obtained p r i o r to each set of blood pressure measurements 
and resting E K G s w e r e obtained w i t h i n f i v e minutes after each set of blood pressure 
measurements. Patients then continued to take either placebo or diltiazem in a twice daily 
regimen beginning on day 2 f o r 1 4 days. Patients r e t u r n e d to the clinic on days 3 , 5 , and 
9 f o r repeat E K G s and w e r e interviewed f o r adverse effects. A blood sample f o r serum 
concentration analysis and a set of blood pressure measurements w e r e also obtained on day 
9. On the m o r n i n g of dey 1 6 of the s t u d / , B P measurements, blood samples and E K G s 
w e r e obtained in the same manner as on day 1 of the study- Repeat complete blood count 
w i t h d i f f e r e n t i a l , u r i n a l y s i s and C h e m - 2 0 w e r e obtained the m o r n i n g of day 1 7 of the 
stud/- Placebo and diltiazem w e r e provided b y M a r i o n Laboratories in identically 
appearing tablets. Compliance was assessed b y tablet count on days 9 and 1 6 . Patients 
w e r e dropped f r o m the stud/ i f compliance was less than 8 0 $ . 
Measurements. Blood p r e s s u r e measurements w e r e determined by s p h y g m o -
manometry. The a p p r o p r i a t e blood pressure cuff size as defined b y the A m e r i c a n Heart 
A s s o c i a t i o n 3 3 and the same blood pressure cuff was used f o r repeated measures in each 
patient. Korotkoff sounds I and V w e r e used as the determinants of systolic and diastolic 
p r e s s u r e s , respectively. F o r u p r i g h t p r e s s u r e s , the f o r e a r m was positioned at the 
horizontal level of the f o u r t h intercostal space at the sternum. A l l supine pressures w e r e 
obtained after the patient had been l y i n g in e horizontal position on a flat surface f o r a 
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m i n i m u m of ten minutes. Each recorded set of blood pressures was the average of three 
readings taken at least one minute apart. Upon completion of supine readings, the patient 
stood up and a single blood pressure measurement was obtained and recorded as the 
immediate standing blood pressure. A f t e r the patient stood f o r f i v e minutes, three blood 
pressure measurements, one minute apart w e r e obtained. Heart rate was determined b y 
palpation of the radi8l pulse taken f o r 3 0 seconds in the supine, immediately standing and 
after standing f o r f i v e minutes positions. Electrocardiograms w e r e performed using a 
standard 1 2 - l e a d Hewlett Packard E K Q recorder. Blood samples w e r e drawn f r o m the 
antecubital vein in the a r m opposite the one in which blood pressure measurements w e r e 
taken. Seven m i l l i l i t e r s ( m l ) of blood w e r e obtained f o r each sample w i t h a blood 
collection needle d i r e c t l y into a 1 0 m l Vacutainer® ( B e c t o n - D i c k i n s o n and C o m p a n y , 
R u t h e r f o r d , New J e r s e y ) containing sodium heparin. Samples w e r e immediately placed on 
ice. Processing of the blood sample occurred w i t h i n ten minutes f r o m when the sample 
was drawn. Blood was centrifuged at f i v e degrees centigrade f o r ten minutes at 2 5 0 0 
revolutions per minute. Plasma was t r a n s f e r r e d using a glass pipette into P y r e x ® 
( C o r n i n g Glassworks, C o r n i n g , New Y o r k ) c u l t u r e tubes and f r o z e n in a slanted position at 
- 3 0 degrees centigrade. Samples w e r e packed in d r y ice and shipped to M a r i o n 
Laboratories f o r analysis. S e r u m was analyzed b y high performance liquid 
chromatography ( H P L C ) ( M a r i o n L a b o r a t o r i e s , personnel communication). T h e lower 
l i m i t of s e n s i t i v i t y of the H P L C assay is 6 ng/ml. The between r u n and between day 
coefficients of v a r i a t i o n w e r e 3.95S and 5 . 2 5 1 , respectively. Adverse effects w e r e 
assessed on days 1 , 3 , 5 , 9 and 1 6 . A l l adverse reactions w e r e assessed as to t h e i r 
potential relationship to the study medication as follows: 
Remote-less than two of the four c r i t e r i a listed below. 
P o s s i b l e - a t least two of the four c r i t e r i a listed below. 
P r o b a b l e - a t least three of the c r i t e r i a listed below. 
1. A reasonable temporal relationship between administration of study medication 
and the observed reaction is noted. 
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2 . Readministration of stud/ medication results in reappearance o r worsening 
of the reaction. 
3. P r e v i o u s experience w i t h the suspected or related compounds resulted in 
a s i m i l a r reaction. 
4. No other alternative explanation seems plausible ( s u c h ss the patient's 
preexisting condition, potentially noxious or environmental factors o r other 
modes of therapy administered to the patient). 
Analysis. D e s c r i p t i v e statistics were used f o r patient demographics, blood p r e s s u r e 
response and side effect profile. The number of patients participating in each group was 
too small and the v a r i a b i l i t y in measurements too greet to w a r r a n t inferential statistical 
evaluation. Spearman correlation W8S used to determine whether a correlation between 
dose and serum concentration or serum concentration and blood pressure effect existed. 
R E S U L T S 
Twenty six patients w e r e randomized and completed the t r i a l . O n l y 2 1 patients met 811 
c r i t e r i a f o r e n t r y . In three patients, the baseline blood pressure measurements had been 
obtained more frequently th8n the time stated f o r stabilization b y e n t r y c r i t e r i a . A n 
additional two patients had baseline diastolic blood pressures which w e r e less than the 
9 5 m m H g required f o r qualification into the stud/. These f i v e patients w e r e excluded 
f r o m the blood p r e s s u r e response analysis but included in the evaluation of adverse 
effects. 
Patient demographics of those qualifying for the stud/ are listed in Table 1. A n unequal 
distribution of female patients occurred despite randomization. No black patients entered 
the stud/. Other variables such as age, height, weight , duration of hypertension and 
baseline blood pressures were s i m i l a r among treatment groups. A l l but three patients, 
one in each of the three diltiazem treatment groups, had been on antihypertensive 
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medications immediately p r i o r to enrollment into t h i s stud/. 
O r i g i n a l l y six patients each w e r e randomized to placebo and the 1 2 0 m g diltiazem 
treatment g r o u p s , w h i l e seven patients each w e r e in the 6 0 m g and 1 8 0 m g diltiazem 
groups. Due to the reasons stated above, two patients each w e r e dropped f r o m the placebo 
and 6 0 m g diltiazem subset and one patient was dropped f r o m the 1 8 0 m g diltiazem 
treetment group ( F i g u r e 1 ) . T h e r e W8S 10051 compliance in all patients determined b y 
tablet counts on days 9 and 1 6 . 
O n l y changes in supine diastolic blood pressures w e r e analyzed. D i u r n a l v a r i a t i o n in 
blood pressure was evident b y the marked reduction in diastolic blood pressure compared 
to baseline noted In all groups in the m o r n i n g on day 1 of the stud/ p r i o r to drug 
administration ( T a b l e 2 ) . T o reduce the effects of diurnal v a r i a t i o n on blood pressure 
response, evaluations of changes in blood p r e s s u r e w e r e performed only at those times 
d u r i n g treatment which correlated w i t h the approximate t i m e of day at which baseline 
blood pressure evaluations w e r e obtained in the outpatient clinic ( H r s 3 and 4 on days 1 
and 1 5 ) . D a y 9 blood pressures w e r e measured between t w o and three hours after the 
patients took t h e i r m o r n i n g dose w h i c h again correlated w i t h the approximate t i m e of day 
at which baseline blood p r e s s u r e evaluations w e r e obtained and a r e also included in the 
evaluation. Table 2 lists the mean reductions in supine blood pressure b y treatment group 
at each of the evaluated times. A large v a r i a t i o n in blood pressure w i t h i n each group is 
apparent as well as a marked placebo response. O n l y small quantitative differences are 
noted among groups. The mean reduction in supine diastolic blood pressure on day 9 was 
n e a r l y equal among all treetment groups. 
T h e r e was a strong correlation between diltiazem dose and m a x i m u m serum 
concentration achieved on both days 1 and 1 6 ( F i g u r e 2 ) . A large interpatlent v a r i a b i l i t y 
in the m a x i m u m serum concentrations achieved f o r each dose is evident b y the range of 
serum concentrations noted f o r each dose. A poor correlation was found between ser um 
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concentration and supine diastolic blood pressure response In Individual patients 
( T a b l e 3 ) , in individual treatment groups ( F i g u r e 3 ) and in all patients' data combined 
( F i g u r e 4 ) . These correlations w e r e done w i t h serum concentration and blood pressure 
data f r o m days 1 , 9 and 1 6 combined. 
Adverse effects which met the c r i t e r i a of the investigators to be possibly o r p r o b a b l y 
treatment related are listed in Table 4. The total number of patients evaluated In each 
group f o r side effects is indicated in the table. One patient in each group experienced no 
adverse effects. A greater number of adverse effects was reported in the drug treatment 
groups compared to placebo. No patient required discontinuation of treatment due to 
adverse effects o r elevations In blood pressure. The most frequently reported adverse 
effect was headache. In all patients, the incidence and s e v e r i t y of headaches diminished 
w i t h continued therapy. Sinus bradycardia was the second most frequent adverse effect. It 
o c c u r r e d j n near equal frequencies in the diltiazem and placebo treated patients. There did 
not appear to be a greater Incidence w i t h the larger doses. D i z z i n e s s and lightheadedness 
also occurred in near equal frequencies in both the placebo treated and active drug 
treatment groups. Other adverse effects w e r e noted occasionally as indicated in the table. 
One patient receiving 3 6 0 m g per day of diltiazem developed a sinus tachycardia w i t h a 
prolonged QT i n t e r v a l which the investigators felt was r e m o t e l y related to the treetment. 
The patient recovered f r o m this event which was thought to be v8so-vaga1 in origin. T h e 
patient continued in the study and no f u r t h e r episodes w e r e noted on subsequent EKGs. 
No c l i n i c a l l y significant abnormalities or changes in laboratory tests w e r e noted f r o m 
prestudy and poststudy laboratory evaluations. 
D I S C U S S I O N 
T h e goals of this randomized, p a r a l l e l , placebo controlled comparative t r i a l w e r e to 
examine the efficacy of diltiazem In a twice daily dosage regimen f o r the treetment of m i l d 
to moderate essential hypertension and to see If a correlation between serum concentration 
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and blood p r e s s u r e response existed. In spite of a c a r e f u l l y designed stud/ r e q u i r i n g a 
stable, elevated blood pressure f o r e n t r y , a significant reduction in blood pressure 
occurred in the placebo group. V e r y l i t t l e placebo response compared to diltiazem was 
noted b y Pool and c o w o r k e r s 3 2 w h o used s i m i l a r e n t r y c r i t e r i a and dosages of diltiazem. 
Perhaps the marked placebo response in o u r stud/ was due to the circumstances 
surrounding blood pressure measurements. A l l patients were confined to bedrest d u r i n g 
the f i r s t f o u r hours after dosing on days 1 and 1 6 and w e r e subsequently normotensive. 
T h i s does not explain the lack of difference noted between treatment groups on day 9 when 
patients w e r e evaluated under s i m i l a r circumstances as t h e i r baseline measures. Because 
the differences in blood pressures among treatment groups w e r e v e r y small and the 
v a r i a b i l i t y v e r y large, it would take a large sample size to detect a l O m m H g difference o r 
a 1 0 $ decrease in blood pressure expected f r o m drug treatment. 
Other possible reasons for seeing l i t t l e differences between placebo and drug treatment 
groups could be attributed to the duration of drug treatment o r to the effect repeated 
measures on blood pressure. None of the above listed diltiazem t r i a l s 2 6 " 3 2 evaluated the 
effect of diltiazem at less than three weeks of t h e r a p y ; most t r i a l s evaluated diltiazem's 
effects after at least four weeks on d i l t i a z e m . 2 6 " 2 8 , 3 0 - 3 2 T h e r e f o r e , one reason f o r not 
finding a difference between drug treated groups and placebo may have been an insufficient 
length of diltiazem therapy. Another thought is initial blood pressure measurements in a 
new environment may be elevated and subsequently decrease as repeated measures are 
performed and patient comfort w i t h the new situation improves. K a p l a n 3 4 reviewed the 
effect of twice daily blood pressure measurements f o r 3 0 days in 6 0 patients w i t h an 
elevated baseline blood pressure. A 1 0 m m H g or greater reduction in blood pressure was 
noted in 4 3 8 of the patients. W h i l e most of the reduction in diastolic blood pressure 
occurred w i t h i n seven to ten days of repeated measurements, f u r t h e r reduction in blood 
pressure was noted over the 3 0 day period. T h i s effect m a / help explain w h y the placebo 
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group responded so well . 
A final consideration is in regard to the effects on blood p r e s s u r e of antihypertensive 
treatment. It is conceivable that p r i o r antihypertensive t h e r a p y m a / have an effect on 
blood pressure and that w i t h discontinuation of t h e r a p y , patients r e m a i n normotensive. 
Since n e a r l y all patients enrolled in this stud/ w e r e on antihypertensive medications 
p r i o r to e n r o l l m e n t , it is possible that they m a / have become normotensive through the 
course of the t r i a l i r r e s p e c t i v e of diltiazem therapy. T h i s could explain the lack of effect 
detected between the drug treatment groups and placebo. W h i l e this hypothesis has never 
been demonstrated, one placebo-controlled stud/ did reveal in 3 1 patients w i t h a mean 
duration of p r i o r antihypertensive treatment of s i x y e a r s w i t h a d i u r e t i c alone, the meen 
length of t i m e f o r t h e i r blood p r e s s u r e to r e v e r t to a predetermined hypertensive value 
was 2 7 w e e k s . 3 5 The arguments against t h i s hypothesis 8re that all patients had stable 
elevated blood p r e s s u r e p r i o r to the treetment phase of t h i s study and that in one other 
t r i a l in which all patients w e r e on p r i o r antihypertensive t h e r a p y w i t h a s i m i l a r 
duration of washout t i m e as used in o u r s t u d / , diltiazem compared f a v o r a b l y to p l a c e b o . 3 2 
T h e r e was a good correlation between dose and m a x i m u m serum concentration on days 1 
and 1 6 . The interpatient v a r i a b i l i t y between m a x i m u m serum concentration and 
diltiazem dose was v e r y large. Because of the large v a r i a b i l i t y in serum concentration 
among patients receiving the same dose, correlations between serum concentration and 
blood pressure response w e r e f i r s t p e r f o r m e d on individuel patients. O n l y f a i r 
correlations ( r > 0 . 5 ) w e r e noted in a few patients. F u r t h e r correlation analysis between 
serum concentration and blood p r e s s u r e effects b y individual groups and b y combining all 
patients also showed poor correlations. Based on t h i s sample of patients, no correletion in 
serum concentration and blood p r e s s u r e response was detected T h i s result is consistent 
w i t h the data reported b y F r i s h m a n and colleagues 2 9 w h e r e no correlation between serum 
concentration and blood p r e s s u r e effects w e r e noted. 
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Headaches and sinus bradycardia w e r e more frequent in the active treatment groups 
compared to placebo. Headaches w e r e present in n e a r l y all patients in the 1 2 0 m g and 
1 8 0 m g diltiazem dose groups. T h e y w e r e generally well tolerated and diminished w i t h 
continued therapy. The incidence of adverse effects noted in the diltiazem treatment 
groups in t h i s t r i a l is greater when compared to other diltiazem hypertension t r i a l s 2 8 , 3 0 
but o v e r a l l , diltiazem was well tolereted in the dosage regimens employed in this study-
In one r e p o r t transient and r e v e r s i b l e changes in l i v e r function tests w e r e noted w i t h 
diltiazem t h e r a p y . 3 2 No significant alterations in l i v e r function tests o r any other 
laboratory values were detected in o u r t r i a l . These results a r e consistent w i t h those 
reported b y Pool et a l 3 6 w h e r e in an open labelled 1 2 - w e e k t r i a l comparing diltiazem to 
placebo, no changed in serum potassium, u r i c acid o r glucose was found. D i l t i a z e m 
treatment was associated w i t h an increase in H D L - c h o l e s t e r o l and a decrease in total 
cholesterol: H D L - cholesterol ratio. No other changes in serum lipids w e r e noted. The 
authors could not speculate on whether these changes in serum lipids are c l i n i c a l l y 
beneficial. They did suggest that one advantage of calcium channel blockers o v e r 
beta-blockers is the lack of effect of calcium channel blockers on serum chemistries and 
the potential f o r beneficial effects on serum lipids. 
The precise r o l e f o r diltiazem in the treatment of essential hypertension is unclear. 
When considering the comparative cost of diltiazem treetment to other antihypertensive 
agents touted as monotherapy ( T a b l e 5 ) , diltiazem ( C a r d i z e m ® - M a r i o n L a b o r a t o r i e s , 
Kansas C i t y , M i s s o u r i ) is one of the most expensive antihypertensive agents. Its cost is 
second w i l y to nifedipine ( P r o c a r d i a ® - P f i z e r L a b o r a t o r i e s , New Y o r k , New Y o r k ) , 
another calcium antagonist. Based on cost alone, dilitazem would not be considered the 
d r u g of choice f o r initial treatment of essential hypertension in patients w i t h no other 
indication f o r its use. Calcium channel antagonists have been reported to be useful in a 
wide v a r i e t y of disease states including migraine headache, p e r i p h e r a l vascular disease, 
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aortic Insufficiency, congestive heart f a i l u r e , p u l m o n a r y h y p e r t e n s i o n , asthma and 
o t h e r s . 3 7 The use of calcium channel blockers in these disease states is s t i l l 
investigational. B u t , diltiazem m a y p r o v e to be a cost-effective alternative to m u l t i p l e 
drug t h e r a p y in those individuals w i t h hypertension and another coexisting disease f o r 
which calcium channel blockers a r e useful. Kiowski et a l 3 8 considered select hypertensive 
patient populations who m e y respond better to diltiazem. Results of 8n analysis of 1 3 8 
white and 1 6 black hypertensive patients suggest there may be a greater blood p r e s s u r e 
response in older patients ( > 6 0 y e a r s of age) who have low r e n i n a c t i v i t y and possibly in 
black patients as w e l l . 3 8 F u r t h e r investigation is necessary to validate these conclusions. 
C O N C L U S I O N 
In conclusion, diltiazem administration was effective in reducing supine diastolic blood 
pressure. H o w e v e r , due to the large placebo effect, the small sample size and large 
v a r i a b i l i t y in blood pressure response in this s t u d y , no difference in blood p r e s s u r e 
response in the diltiazem treated groups compared to the placebo group was detected. No 
significant correlation W8S found between serum concentrations and blood p r e s s u r e 
response. Adverse experiences w h i l e greater in incidence when compared to other 
diltiazem hypertension t r i a l s , w e r e well tolerated and consistent w i t h the benign side 
effect p r o f i l e of the drug. Due to the potential deleterious effects of diuretics and 
beta-blockers and considering the potential benefit of calcium channel blockers in the 
treatment of a wide v a r i e t y of disease states, continued research into the use of calcium 
channel blockers as antihypertensive agents is w o r t h w h i l e . The precise r o l e of diltiazem 
in the treetment of essential hypertension is yet to be determined. Due to the higher cost 
of diltiazem compared to other monotherapy antihypertensive agents, it would not be 
recommended as the drug of choice f o r single drug treatment of hypertension in patients 
w i t h no other Indication f o r its use. In hypertensive patients w i t h concurrent illnesses 
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which r e q u i r e the use of 8 calcium channel b l o c k e r , diltiazem m a / be justified as 
cost-effective t h e r a p y compared to m u l t i p l e drug treetment. Continued investigetion to 
identify those hypertensive patient populations w h o may respond better to calcium 
channel blocker t h e r a p y is necessary to f u r t h e r delineate the role of diltiazem in the 
management of essentiel hypertension. 
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Table 1. Patient demographics. 
Placebo 6 0 m g 1 2 0 m g 1 8 0 m g 
n - 4 n - 5 n - 6 n - 6 
Sex 
Male 2 5 5 5 
Female 2 0 1 1 
A g e ( y r ) 4 6 ± 5 5 0 ± 1 3 5 0 ± 1 2 4 8 ± 7 
Height ( i n ) 7 0 ± 5 7 1 ± 2 7 1 ± 2 6 9 ± 5 
Weight ( l b s ) 1 6 9 ± 3 8 1 7 8 ± 1 2 1 8 1 ± 2 5 1 8 3 ± 4 2 
Hypertension 
Duration ( y r ) 5 ± 6 5 ± 4 7 ± 4 6 ± 5 
P r i o r treatment 
Yes 4 4 5 5 
No 0 1 1 1 
Baseline B P ( m m H g ) 
Systolic 1 4 9 . 0 ± 7 . 6 
Diastolic 1 0 1 . 0 ± 6 . 4 
1 4 2 . 6 ± 6 . 0 
9 8 . 8 ± 4 . 0 
1 5 6 . 6 ± 1 7 . 6 1 5 2 . 3 ± 1 2 . 5 
1 0 4 . 6 ± 4 . 8 1 0 2 . 3 ± 4 . 7 
Table 2. Decreases in diastolic blood pressure ( m m H g ) f r o m baseline. Mean ± S D ( r a n g e ) 
Placebo 
n = 4 
6 0 m g 
n = 5 
1 2 0 m g 
n = 6 
1 8 0 m g 
n = 6 
D a y l H r O 1 1 . 5 ± 1 5 . 0 
( - 4 to 2 8 ) * 
1 0 . 8 ± 2 . 5 
( 8 to 1 5 ) 
7 . 8 ± 8 . 4 
( - 2 to 2 0 ) * 
9 . 1 ± 7 . 4 
( O t o 1 9 ) 
D a y l H r 3 1 9 . 2 ± 1 3 . 0 
( 4 to 3 2 ) 
1 7 . 6 ± 5 . 3 
( 1 2 to 2 5 ) 
1 7 . 3 t  8 . 7 
( 7 to 3 3 ) 
1 8 . 3 ± 7 . 6 
( 4 to 2 5 ) 
D a y l H r 4 1 6 . 5 ± 1 0 . 3 
( 4 to 2 5 ) 
1 5 . 6 ± 6 . 2 
( 5 to 2 0 ) 
1 3 . 5 ± 1 3 . 3 
( - 4 to 3 7 ) * 
2 1 . 8 ± 7 . 4 
( 1 4 to 3 3 ) 
Day 9 1 0 . 7 ± 1 2 . 6 
( - 7 to 2 2 ) * 
1 0 . 8 ± 6 . 5 
( 2 to 1 9 ) 
1 0 . 5 ± 4 . 3 
( 5 t o 1 8 ) 
1 1 . 8 ± 8 . 2 
( O t o 2 3 ) 
D a y 1 6 H r 3 1 5 . 8 ± 7 . 1 
( 5 to 2 5 ) 
1 8 . 0 ± 1 3 . 1 
( 5 to 3 5 ) 
2 0 . 0 ± 9 . 0 
( 8 to 2 8 ) 
2 2 . 3 ± 7 . 4 
( 1 4 to 3 5 ) 
D a y 1 6 H r 4 1 6 . 0 ± 1 2 . 7 
( 2 to 3 0 ) 
1 2 . 4 ± 6 . 9 
( 3 to 2 2 ) 
2 0 . 3 ± 3 . 0 
( 1 5 to 2 3 ) 
2 2 . 0 ± 4 . 1 
( 1 7 to 2 9 ) 
" N e g a t i v e value indicates an increase in diastolic blood p r e s s u r e f r o m baseline. 
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Table 3. Spearman correlation f o r serum concentration and decrease in diastolic blood 
pressure f o r Individual patients. 
Patient No. Dose r 8 P b 
8 6 0 m g 0 . 1 4 7 0 . 5 4 7 
1 2 6 0 m g - 0 . 3 5 2 * 0 . 1 5 2 
1 4 6 0 m g 0 . 2 3 8 0 . 4 1 2 
2 4 6 0 m g 0 . 5 4 4 0 . 0 6 8 
1 1 4 6 0 m g 0 . 4 0 5 0 . 0 6 2 
1 1 2 0 m g 0 . 5 1 1 0 . 0 1 5 
7 1 2 0 m g 0 . 1 3 4 0 . 5 5 2 
1 1 1 2 0 m g 0 . 4 3 4 0 . 0 4 3 
1 5 1 2 0 m g 0 . 5 4 7 0 . 0 1 0 
" 2 1 1 2 0 m g 0 . 5 9 7 0 . 0 4 1 
1 0 1 1 2 0 m g 0 . 5 1 9 0 . 0 1 6 
6 1 8 0 m g 0 . 2 6 0 0 . 2 4 3 
9 1 8 0 m g - 0 . 1 3 1 * 0 . 5 8 3 
1 3 1 8 0 m g 0 . 4 4 8 0 . 0 3 7 
1 7 1 8 0 m g 0 . 2 6 5 0 . 2 3 3 
2 0 1 8 0 m g 0 . 2 5 7 0 . 2 7 1 
2 3 1 8 0 m g 0 . 4 6 7 0 . 1 2 5 
a. r i 0 . 8 5 indicates a good correlation. 
b. p i 0 . 0 5 indicates a statistically significant correlation. 
* Negative values for r indicates a negative c o r r e l a t i o n , a decrease In blood p r e s s u r e 
w i t h an increase in serum concentration. 
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Table 4 . Adverse effects b y treatment group. 
Placebo 6 0 m g 1 2 0 m g 1 8 0 m g 
n = 6 n = 7 n = 6 n = 7 
Headache 1 3 6 5 
Dizzy/lightheaded 3 2 0 1 
Sinus bradycardia 2 3 2 2 
F i r s t degree AV btock 0 1 1 0 
Fatigue/weakness 0 1 0 0 
U r i n a r y frequency 0 0 3 0 
Increased u r i n e volume 0 0 0 1 
Hot f lash/flushing 0 0 0 2 
Vomiting 0 0 0 1 
Nausea 0 0 0 1 
Sinus bradycardia w i t h 0 1 1 0 
prolonged QT i n t e r v a l 
Prolonged QT i n t e r v a l 0 1 0 1 
T - w a v e inversion 0 1 0 0 
Total 5 1 3 1 3 M 
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Table 5. Cost comparison of monotherapy antihypertensive agents. 
Total daily A W P Patient 
D r u g Regimen dose ( m g ) Cost/dey C o s t / d e y * 
H C T Z 8 2 5 - 5 0 m g q d 2 5 - 5 0 < 0 . 0 1 < 0 . 0 4 
H y d r o d i u r i l ® 2 5 - 5 0 m g q d 2 5 - 5 0 0 . 0 6 - 0 . 1 0 0 . 0 9 - 0 . 1 3 
Dyazide® i - i i q d i - l i 0 . 2 1 - 0 . 4 3 0 . 1 9 - 0 . 3 8 
M a x z i d e ® 1-11 qd 1 - 1 1 0 . 2 1 - 0 . 4 2 0 . 2 5 - 0 . 4 8 
P r o p r a n o l o l 4 0 - 8 0 m g bid 8 0 - 1 6 0 0 . 0 6 - 0 . 1 0 0 . 0 8 - 0 . 1 2 
Inderal® 4 0 - 8 0 m g bid 8 0 - 1 6 0 0 . 1 1 - 0 . 1 9 0 . 1 3 - 0 . 2 1 
Inderal L A ® 8 0 - 1 6 0 m g qd 8 0 - 1 6 0 0 . 3 6 - 0 . 5 8 0 . 3 9 - 1 . 2 3 
T e n o r m i n ® 5 0 - 1 0 O m g qd 5 0 - 1 0 0 0 . 4 4 - 0 . 6 5 0 . 4 7 - 0 . 6 8 
L o p r e s s o r ® 2 5 - 1 0 0 m g bid 5 0 - 2 0 0 0 . 2 3 - 0 . 8 2 0 . 2 6 - 0 . 8 8 
Normodyne® 1 0 0 - 4 0 0 m g bid 2 0 0 - 8 0 0 0 . 3 4 - 1 . 0 4 0 . 4 1 - 1 . 1 6 
M i n i p r e s ® 1 - 5 m g bid 2 - 1 0 0 . 3 1 - 0 . 7 4 0 . 3 4 - 0 . 8 1 
Catapres® 0 . 1 - 0 . 3 m g bid 0 . 2 - 0 . 6 0 . 1 3 - 0 . 5 0 0 . 1 5 - 0 . 2 7 
C a r d i z e m ® 6 0 - 1 8 0 m g bid 1 2 0 - 3 6 0 0 . 7 8 - 1 . 5 6 0 . 8 4 - 2 . 5 2 
Calan® 8 0 - 1 2 0 m g tid 2 4 0 - 3 6 0 0 . 8 4 - 1 . 1 2 0 . 9 3 - 1 . 2 3 
P r o c a r d i a ® 1 0 t i d - 3 0 qid 3 0 - 1 2 0 0 . 6 9 - 2 . 7 0 0 . 7 9 - 2 . 8 4 
Capoten® 6 . 2 5 - 2 5 m g t i d 1 8 . 7 5 - 7 5 0 . 3 8 - 0 . 8 3 0 . 4 3 - 0 . 9 4 
Vasotec® 5 - 2 0 m g bid 1 0 - 4 0 0 . 8 8 - 1 . 3 2 0 . 9 5 - 1 . 3 9 
* B a s e d on a local chain store patient charge. 
8 Rugby generic hydrochlorothiazide. 
b Lederle generic propranolol 
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F i g u r e 1 . Patient Randomization. T w e n t y six patients completed the t r i a l . 
One patient each f r o m the placebo, 6 0 m g and 1 8 0 m g treatment 
groups were dropped f r o m the blood pressure effects analyses 
because baseline blood pressures w e r e measured m o r e frequently 
than the t i m e stated f o r stablization b y e n t r y c r i t e r i a . One patient 
each in the placebo and 6 0 m g groups w e r e excluded because t h e i r 
qualifying blood pressures w e r e <95mmHg. 
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F i g u r e 2. Scatter grams and Spearman correlations f o r dose and m a x i m u m serum 
concentration for days 1 and 1 6 . r i 0 . 8 5 indicates a good correlation. 
P 4 0 . 0 5 Indicates a statistically significant correlation. 
• S e r u m concentration data f o r one patient in each of the treetment groups was not 
available f o r day 1. 
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F i g u r e 4. Scatter gram and Spearman correlation for serum concentration and 
decrease in diastolic blood pressure for all patients collectively for deta 
f r o m dtys 1 , 9 and 1 6 combined. r i 0 . 8 5 Indicates a good correlation. 
P 4 0 . 0 5 indicates a statistically significant correlation. 
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A P P E N D I X I 
H e i g h t - W e i g h t Table 
M E N W O M E N 
Height Small Medium Large Height Small Medium Large 
( i n ) F r a m e F r a m e F r a m e ( i n ) F r a m e F r a m e F r a m e 
6 2 1 3 1 1 3 6 1 4 4 5 8 1 0 7 1 1 5 1 2 5 
6 3 1 3 3 1 3 8 1 4 7 5 9 1 0 8 1 1 7 1 2 7 
6 4 1 3 5 1 4 0 1 4 9 6 0 1 1 0 1 2 0 1 3 0 
6 5 1 3 7 1 4 3 1 5 2 6 1 1 1 2 1 2 2 1 3 3 
6 6 1 3 9 1 4 5 1 5 5 6 2 1 1 5 1 2 5 1 3 6 
6 7 1 4 2 1 4 8 1 5 9 6 3 1 1 8 1 2 8 1 3 9 
6 8 1 4 4 1 5 1 1 6 2 6 4 1 2 1 1 3 1 1 4 3 
6 9 1 4 7 1 5 4 1 6 6 6 5 1 2 4 1 3 4 1 4 6 
7 0 1 4 9 1 5 7 1 6 9 6 6 1 2 7 1 3 7 1 5 0 
7 1 1 5 2 1 6 0 1 7 3 6 7 1 3 0 1 4 0 1 5 3 
7 2 1 5 5 1 6 4 1 7 6 6 8 1 3 3 1 4 3 1 5 7 
7 3 1 5 8 1 6 7 1 8 0 6 9 1 3 6 1 4 6 1 6 0 
7 4 1 6 2 1 7 1 1 8 5 7 0 1 3 9 1 4 9 1 6 3 
7 5 - 1 6 5 1 7 5 1 8 9 7 1 1 4 2 1 5 2 1 6 6 
7 6 1 6 9 1 7 9 1 9 4 7 2 1 4 5 1 5 5 1 6 9 
How to Determine Bod/ F r a m e b y Elbow Breadth 
To determine f r a m e size extend the a r m and bend the f o r e a r m upwards at a 9 0 degree 
angle. Keep the fingers straight end t u r n the inside of the w r i s t away f r o m the bod/. 
Measure the distance between the two prominent bones on either side of the elbow. 
Compare the measurement w i t h the following tables. 
These tables list the elbow measurements f o r m e d i u m - f r a m e d men and women of 
v a r i o u s heights. Measurements lower than those listed Indicate a small f r a m e and higher 
measurements indicate a large frame. 
M E N W O M E N 
Height in 1 " heels Elbow Breadth Height in 1 " heels Elbow Breadth 
5 ' 2"  - 5' 3 " 2 1 / 2 " - 2 7 / 8 " 4 ' 1 0 " - 4 ' 1 1 " 2 1 / 4 " - 2 1 / 2 " 
5" 4 " - 5' 7 " 2 5 / 8 " - 2 7 / 8 " 5' 0 " - 5' 3 " 2 1 / 4 " - 2 1 / 2 " 
5' 8 " - 5 ' 1 1 " 2 3 / 4 " - 3 " 5 ' 4 " - 5 ' 7 " 2 3 / 8 " - 2 5 / 8 " 
6' 0 " - 6' 3 " 2 3 / 4 " - 3 1 / 8 " 5" 8 " - 5 ' 1 1 " 2 3 / 8 " - 2 5 / 8 " 
6' 4 " - 2 7 / 8 " - 3 1 / 4 " 6' 0 " - 2 1 / 2 " - 2 3 / 4 " 
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D l l t l a z e m Versus Placebo In Hypertension 
You are being invited to participate in a research project that w i l l evaluate the use of 
diltiazem ( C a r d i z e m ® , M a r i o n L a b o r a t o r i e s ) in patients w i t h m i l d to moderate 
hypertension. T h i s is an investigational d r u g stud/ and you w i l l be under the medical 
supervision of L a r r y S t a k e r , M . D . D i l t i a z e m is a d r u g that relaxes blood vessels. It is 
c u r r e n t l y approved b y the F D A ( F o o d and D r u g A d m i n i s t r a t i o n ) to treat patients w i t h 
heart related chest pain (angina). T h i s stud/ w i l l evaluate the safety and effectiveness of 
diltiazem 8s compared to placebo (sugar p i l l ) on blood pressure and heart rate. It w i l l 
also determine the p r o p e r dose. 
P R O C E D U R E S 
T h i s stud/ w i l l be conducted over a m i n i m u m of 2 9 days and a m a x i m u m of 4 5 days 
divided In the following manner. You w i l l be asked to stop talcing y o u r blood p r e s s u r e 
medications i f you c u r r e n t l y take some for the duration of the stud/- T h e r e w i l l be a 1 4 to 
2 8 da/ screening period followed b y a 1 5 day treatment period. D r . Staker o r D r . Nappi 
must approve any other medications ( e i t h e r prescription o r n o n - p r e s c r i p t i o n such as 
a s p i r i n ) you take d u r i n g the stud/. 
D r r Staker w i l l determine i f you a r e eligible f o r this stud/ during the screening period. 
On the f i r s t v i s i t you w i l l have a medical h i s t o r y , physical examination, chest x - r a y i f 
you have not had one in the last s i x months, 1 0 m l of blood drawn f r o m y o u r v e i n ( 2 
teespoonfuls), u r i n e sample, measurement of blood p r e s s u r e and heart rate and an 
electrocardiogram ( E C 0 ) w h i c h is an electrical tracing of y o u r heart. You w i l l r e t u r n to 
the clinic once each week to determine i f y o u r heart rate and blood pressure a r e w i t h i n the 
stud/ guidelines. I f y o u meet the guidelines you w i l l be eligible to enter the treatment 
period. You w i l l be assigned to one o f four treatments; placebo o r 6 0 m g , 1 2 0 o r 1 8 0 m g 
of diltiazem twice a day. Neither D r s . Staker o r Nappi o r y o u w i l l know which medication 
you receive. On Day 1 end D o / 1 6 of the treatment period, y o u w i l l be in the hospital f o r 
2 4 hours. D u r i n g that t i m e y o u w i l l allow the following to be done 1 1 times at 
specifically designated t i m e periods: blood p r e s s u r e and heart rate measurements, E C O 
recordings, and blood drawn out of y o u r v e i n ( 1 0 m l each t i m e f o r a total of 3 - 1 / 2 
ounces), after taking a single dose of the medication. You w i l l be given a meal at specific 
times twice on those days. On Day 3 and Day 5 you w i l l come to the hospital to get an E C O 
taken. On Day 9 you w i l l come to the hospital to get y o u r blood pressure and heart rate 
measured, an E C O Ween, 1 0 m l of blood drawn out of y o u r v e i n and asked about adverse 
effects. You should n o t i f y D r s . Staker o r Nappi at any time during the stud/ if y o u have 
any unusual signs o r symptoms. 
D I S C O M F O R T S A N D R I S K S 
T h e following side effects have been reported w i t h diltiazem: edema ( f l u i d in the 
e x t r e m i t i e s ) , headache, neausea, dizziness, r a s h , weakness, and a slow heart rate. T h e r e 
Consent to P a r t i c i p a t e in a Research Stud/ 
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m o / be other unexpected side effects. You w i l l be monitored f o r side effects and i f 
indicated, the drug w i l l be discontinued. 
T h e r i s k s of stopping all y o u r blood pressure medications f o r a short period of t i m e is 
that y o u r blood pressure may increase. Such increases f o r a short period of time should 
not cause any problems. Nonetheless, you w i l l have y o u r blood pressure checked at least 
once a week d u r i n g the screening period, and several times d u r i n g the treatment period. It 
is v e r y important to come In f o r these clinic v i s i t s to get y o u r blood pressure checked. 
The discomfort associated w i t h getting y o u r blood drawn Is soreness and b r u i s i n g at the 
site. 
B E N E F I T S 
A l l y o u r medical care and tests w i l l be provided to you at no charge. In addition you 
w i l l receive payment f o r the inconvenience and t i m e you spend participating in the stud/. 
A L T E R N A T I V E T R E A T M E N T S 
I f you decide not to participate In the s t u d / , there are many drugs that are c u r r e n t l y 
available to treat hypertension. 
C O N F I D E N T I A L I T Y 
Y o u r medical records w i l l be kept confidential and y o u w i l l not be Identified in any 
personal w a y In talks or papers on the stud/ results. H o w e v e r , y o u r medical records may 
be inspected b y the sponsor ( M a r i o n L a b o r a t o r i e s ) , o r the F D A to assess compliance w i t h 
the stud/ protocol. 
I f you have questions about the study at any t i m e , you should contact D r . J e a n Nappi 
5 8 2 - 1 5 6 5 beeper 2 9 3 (available 2 4 h o u r s / d a y ) , or D r . L a r r y Staker 5 8 1 - 7 8 1 8 . I f 
you have a question or problem that cannot be discussed w i t h the Investigators, you may 
call the IRB (Institutional Review Board) office at 5 8 1 - 3 6 5 5 . 
Y o u r participation in this stud/ is completely v o l u n t a r y and you m o / choose to 
withdraw f r o m the stud/ at any time. If you choose to w i t h d r a w , it w i l l not influence the 
medical care that you receive In the f u t u r e in any w o / . 
M E D I C A L T R E A T M E N T O R C O M P E N S A T I O N F O R P H Y S I C A L I N J U R Y 
In the event you sustain physical i n j u r y resulting f r o m the research project in which 
you are participating, the U n i v e r s i t y of Utah w i l l provide y o u , without charge, emergency 
and t e m p o r a r y medical treatment not otherwise covered b y insurance. F u r t h e r m o r e , I f 
y o u r i n j u r i e s are caused b y negligent acts o r omissions of U n i v e r s i t y employees acting in 
the course and scope of t h e i r e m p l o y m e n t , the U n i v e r s i t y may be l iable, subject to 
limitations prescribed b y l a w , for additional medical costs and other damages you sustain. 
Consent to P a r t i c i p a t e in a Research Stud/ 
Diltiazem Versus Placebo in Hypertension 
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If y o u believe you have suffered a physical I n j u r y 8S a result of participation in this 
research p r o g r a m , please contact the Office of Research A d m i n i s t r a t i o n , telephone number 
5 8 1 - 6 9 0 3 . 
C O M P E N S A T I O N F R O M S P O N S O R 
In the event you experience any adverse reaction to this investigational drug during the 
course of this s t u d / , y o u should Immediately contact D r . Nappi o r D r . Staker. 
Reimbursement f o r reasonable medical expenses associated w i t h the treatment of such 
reaction w i l l be provided b y the sponsor, i f in the opinion of the investigator and the 
sponsor the reaction was caused b y the proper use of the drug In accordance w i t h the 
t e r m s of the stud/. N o other compensation w i l l be made available f r o m the sponsor. 
Y o u r signature indicates that you have read this consent f o r m , understand its contents 
and f r e e l y chosose to participate. You also understand that the sponsor and/or investigator 
may also w i t h d r a w y o u f r o m the study i f it is appropriate. 
Signature of Volunteer Date Signature of Investigator 
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